Accelerated sinus rhythm prevents catecholaminergic polymorphic ventricular tachycardia in mice and in patients

Circulation Research

Volumn 112, Issue 4, 2013, Pages 689-697

  Faggioni, Michela ^a   Hwang, Hyun Seok ^a   Van Der Werf, Christian ^b   Nederend, Ineke ^b   Kannankeril, Prince J ^a   Wilde, Arthur A M ^b   Knollmann, Björn C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

arrhythmia suppression; catecholaminergic polymorphic ventricular tachycardia; parasympathetic tone

Indexed keywords

ATROPINE; CATECHOLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CONTROLLED STUDY; EXERCISE TEST; HEART BEAT; HEART PACING; HEART RATE; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINUS RHYTHM; SUPRAVENTRICULAR TACHYCARDIA;

ADULT; ANIMALS; ATROPINE; BRADYCARDIA; CAFFEINE; CALCIUM SIGNALING; CALSEQUESTRIN; CARDIAC PACING, ARTIFICIAL; EXERCISE TEST; HEART RATE; HUMANS; ISOPROTERENOL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; MYOCYTES, CARDIAC; RANDOM ALLOCATION; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SINOATRIAL NODE; SYMPATHECTOMY, CHEMICAL; TACHYCARDIA, VENTRICULAR; VAGUS NERVE; VENTRICULAR PREMATURE COMPLEXES;

EID: 84874225386     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.111.300076     Document Type: Article

References (46)

1. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation. 1995;91:1512-1519.
2. Postma AV, Denjoy I, Kamblock J, Alders M, Lupoglazoff JM, Vaksmann G, Dubosq-Bidot L, Sebillon P, Mannens MM, Guicheney P, Wilde AA. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow-up of the patients. J Med Genet. 2005;42:863-870.
3. Swan H, Piippo K, Viitasalo M, Heikkilä P, Paavonen T, Kainulainen K, Kere J, Keto P, Kontula K, Toivonen L. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol. 1999;34:2035-2042.
4. Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, Levy-Nissenbaum E, Khoury A, Lorber A, Goldman B, Lancet D, Eldar M. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet. 2001;69:1378-1384.
5. Postma AV, Denjoy I, Hoorntje TM, Lupoglazoff JM, Da Costa A, Sebillon P, Mannens MM, Wilde AA, Guicheney P. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2002;91:e21-e26.
6. Roux-Buisson N, Cacheux M, Fourest-Lieuvin A, et al. Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human. Hum Mol Genet. 2012;21:2759-2767.
7. Kang G, Giovannone SF, Liu N, Liu FY, Zhang J, Priori SG, Fishman GI. Purkinje cells from RyR2 mutant mice are highly arrhythmogenic but responsive to targeted therapy. Circ Res. 2010;107:512-519.
8. Stuyvers BD, Dun W, Matkovich S, Sorrentino V, Boyden PA, ter Keurs HE. Ca2+ sparks and waves in canine purkinje cells: a triple layered system of Ca2+ activation. Circ Res. 2005;97:35-43.
9. Rizzi N, Liu N, Napolitano C, et al. Unexpected structural and functional consequences of the R33Q homozygous mutation in cardiac calsequestrin: a complex arrhythmogenic cascade in a knock in mouse model. Circ Res. 2008;103:298-306.
10. Knollmann BC, Chopra N, Hlaing T, Akin B, Yang T, Ettensohn K, Knollmann BE, Horton KD, Weissman NJ, Holinstat I, Zhang W, Roden DM, Jones LR, Franzini-Armstrong C, Pfeifer K. Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest. 2006;116:2510-2520.
11. Kashimura T, Briston SJ, Trafford AW, Napolitano C, Priori SG, Eisner DA, Venetucci LA. In the RyR2(R4496C) mouse model of CPVT, β-adrenergic stimulation induces Ca waves by increasing SR Ca content and not by decreasing the threshold for Ca waves. Circ Res. 2010;107:1483-1489.
12. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, DeSimone L, Coltorti F, Bloise R, Keegan R, Cruz Filho FE, Vignati G, Benatar A, DeLogu A. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106:69-74.
13. Sedej S, Heinzel FR, Walther S, Dybkova N, Wakula P, Groborz J, Gronau P, Maier LS, Vos MA, Lai FA, Napolitano C, Priori SG, Kockskämper J, Pieske B. Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. Cardiovasc Res. 2010;87:50-59.
14. Song L, Alcalai R, Arad M, Wolf CM, Toka O, Conner DA, Berul CI, Eldar M, Seidman CE, Seidman JG. Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia. J Clin Invest. 2007;117:1814-1823.
15. Cerrone M, Colombi B, Santoro M, di Barletta MR, Scelsi M, Villani L, Napolitano C, Priori SG. Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. Circ Res. 2005;96:e77-e82.
16. Joshi P, Saxena A, Kaul U, Mansoor AH. Catecholaminergic polymorphic ventricular tachycardia with associated sinus node dysfunction. Indian Heart J. 2010;62:84-86.
17. Sumitomo N, Sakurada H, Taniguchi K, Matsumura M, Abe O, Miyashita M, Kanamaru H, Karasawa K, Ayusawa M, Fukamizu S, Nagaoka I, Horie M, Harada K, Hiraoka M. Association of atrial arrhythmia and sinus node dysfunction in patients with catecholaminergic polymorphic ventricular tachycardia. Circ J. 2007;71:1606-1609.
18. Han J, DeTraglia J, Millet D, Moe GK. Incidence of ectopic beats as a function of basic rate in the ventricle. Am Heart J. 1966;72:632-639.
19. Zipes DP. The clinical significance of bradycardic rhythms in acute myocardial infarction. Am J Cardiol. 1969;24:814-825.
20. Goel BG, Han J. Atrial ectopic activity associated with sinus bradycardia. Circulation. 1970;42:853-858.
21. Zhou Q, Xiao J, Jiang D, et al. Carvedilol and its new analogs suppress arrhythmogenic store overload-induced ca(2+) release. Nat Med. 2011
22. Bhuiyan ZA, van den Berg MP, van Tintelen JP, Bink-Boelkens MT, Wiesfeld AC, Alders M, Postma AV, van Langen I, Mannens MM, Wilde AA. Expanding spectrum of human RYR2-related disease: new electrocardiographic, structural, and genetic features. Circulation. 2007;116:1569-1576.
23. van der Werf C, Nederend I, Hofman N, et al. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives. Circ Arrhythm Electrophysiol. 2012;5:748-756.
24. Goodman LS, Brunton LL, Chabner B, Knollmann BC. Goodman & Gilman's Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 2011.
25. Dhingra RC, Amat-Y-Leon F, Wyndham C, Denes P, Wu D, Pouget JM, Rosen KM. Electrophysiologic effects of atropine on human sinus node and atrium. Am J Cardiol. 1976;38:429-434.
26. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AA, Knollmann BC. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15:380-383.
27. Priori SG, Chen SR. Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis. Circ Res. 2011;108:871-883.
28. Herron TJ, Milstein ML, Anumonwo J, Priori SG, Jalife J. Purkinje cell calcium dysregulation is the cellular mechanism that underlies catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2010;7:1122-1128.
29. Li P, Rudy Y. A model of canine purkinje cell electrophysiology and Ca(2+) cycling: rate dependence, triggered activity, and comparison to ventricular myocytes. Circ Res. 2011;109:71-79.
30. Liu N, Colombi B, Memmi M, Zissimopoulos S, Rizzi N, Negri S, Imbriani M, Napolitano C, Lai FA, Priori SG. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ Res. 2006;99:292-298.
31. Bennett MA, Pentecost BL. Suppression of ventricular tachyarrhythmias by transvenous intracardiac pacing after acute myocardial infarction. Br Med J. 1970;4:468-470.
32. Naito S, Tada H, Kaneko T, Oshima S, Taniguchi K. Biatrial epicardial pacing prevents atrial fibrillation and confers hemodynamic benefits after coronary artery bypass surgery. Pacing Clin Electrophysiol. 2005;28 (suppl 1):S146-S149.
33. Mont L, Ruiz-Granell R, Martínez JG, Carmona JR, Fidalgo M, Cobo E, Riera M, Navarro X; Prevention or Termination (POT) Study Investigators. Impact of anti-tachycardia pacing on atrial fibrillation burden when added on top of preventive pacing algorithms: results of the prevention or termination (POT) trial. Europace. 2008;10:28-34.
34. Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM, Klug D, Hayashi M, Takatsuki S, Villain E, Kamblock J, Messali A, Guicheney P, Lunardi J, Leenhardt A. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009;119:2426-2434.
35. van der Werf C, Zwinderman AH, Wilde AA. Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments. Europace. 2012;14:175-183.
36. Haugaa KH, Leren IS, Berge KE, Bathen J, Loennechen JP, Anfinsen OG, Früh A, Edvardsen T, Kongsgård E, Leren TP, Amlie JP. High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening. Europace. 2010;12:417-423.
37. Hilliard FA, Steele DS, Laver D, Yang Z, Le Marchand SJ, Chopra N, Piston DW, Huke S, Knollmann BC. Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass. J Mol Cell Cardiol. 2010;48:293-301.
38. Lehnart SE, Wehrens XH, Marks AR. Calstabin deficiency, ryanodine receptors, and sudden cardiac death. Biochem Biophys Res Commun. 2004;322:1267-1279.
39. Hwang HS, Hasdemir C, Laver D, Mehra D, Turhan K, Faggioni M, Yin H, Knollmann BC. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol. 2011;4:128-135.
40. van der Werf C, Kannankeril PJ, Sacher F, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2011;57:2244-2254.
41. Wilson ME, Lee GK, Chandra A, Kane GC. Central anticholinergic syndrome following dobutamine-atropine stress echocardiography. Echocardiography. 2011;28:E205-E206.
42. Richter S, Gebauer R, Hindricks G, Brugada P. A classic electrocardiographic manifestation of catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Electrophysiol. 2012;23:560.
43. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415: 198-205.
44. Sumitomo N, Nakamura T, Fukuhara J, Nakai T, Watanabe I, Mugishima H, Hiraoka M. Clinical effectiveness of pulmonary vein isolation for arrhythmic events in a patient with catecholaminergic polymorphic ventricular tachycardia. Heart Vessels. 2010;25:448-452.
45. Blinks JR. Field stimulation as a means of effecting the graded release of autonomic transmitters in isolated heart muscle. J Pharmacol Exp Ther. 1966;151:221-235.
46. Thomas VC, Law IH, Evans WN. Cardioversion of intraatrial reentrant tachycardia using rate response. Pacing Clin Electrophysiol. 2012;35:e199-e202.